Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

China flag China · Delayed Price · Currency is CNY
57.19
+3.79 (7.10%)
Jul 9, 2025, 3:00 PM CST
45.86%
Market Cap 354.63B
Revenue (ttm) 29.19B
Net Income (ttm) 6.84B
Shares Out 6.63B
EPS (ttm) 1.09
PE Ratio 48.93
Forward PE 42.79
Dividend 0.20 (0.37%)
Ex-Dividend Date May 23, 2025
Volume 115,821,169
Average Volume 44,569,033
Open 53.40
Previous Close 53.40
Day's Range 53.02 - 57.94
52-Week Range 38.01 - 57.53
Beta 0.36
RSI 69.96
Earnings Date Aug 21, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra... [Read more]

Sector Healthcare
Founded 1970
Employees 20,238
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600276
Full Company Profile

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.

Financial Statements

News

There is no news available yet.